Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countries , /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies today announced it is actively engaging with regional distribution partners to make LYMPHIRâ"¢ (denileukin diftitox-cxdl) available to eligible patients through coun ...